Figure 2From: A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation(A) Household conditions and (B) exposure to tobacco smoke (N = 100). *n = 47.Back to article page